Latest Healthcare News

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Argent BioPharma has restructured its acquisition of AusCann assets to sharpen its clinical focus and secured a substantial A$11 million financing facility, positioning itself for growth in 2026.

InteliCare Holdings has advanced its aged care technology deployments and is close to appointing a new CEO, signalling a pivotal growth phase. The company also reported progress in commercial talks and product enhancements.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

InhaleRx Limited has progressed its clinical trials for three drug candidates targeting cancer pain, panic disorder, and treatment-resistant depression, while securing additional funding and preparing for a company rebrand.

Inhalerx Limited reported a $628,000 cash burn in the December quarter while securing substantial funding facilities to advance its clinical trials. The company’s cash position and financing arrangements suggest a runway extending over 80 quarters at current spending levels.

ECS Botanics Holdings Ltd has seen its ECSO securities suspended from ASX quotation due to non-compliance with listing rules, raising questions about the company’s next steps.

Wellnex Life reports a significant turnaround with a 31.5% revenue increase and near break-even operating cash flow in the December quarter, driven by strategic brand consolidation and cost discipline.